載入...
Clinicopathologic and Genomic Characterization of PD‐L1 Positive Urothelial Carcinomas
INTRODUCTION: Pembrolizumab was approved with an accompanying companion diagnostic (CDx) assay (PD‐L1 DAKO 22C3) for urothelial carcinoma (UC). In this study, we further characterize the clinicopathologic and genomic features of UC that are programmed death‐ligand 1 (PD‐L1) positive. MATERIALS AND M...
Na minha lista:
| 發表在: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Inc.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100538/ https://ncbi.nlm.nih.gov/pubmed/33687775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13753 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|